Cardiac manifestations of coronavirus
The myocardial damage shows up to be a common include in COVID-19 and predicts a destitute guess when display. A meta-analysis of six distributed ponders from China found that 8% of patients with COVID-19 had related cardiac damage. A few case arrangements have inspected cardiac protein rises demonstrating myocardial harm that can be auxiliary to ischemic or non-ischemic causes. Other considers have detailed patients with viral myocarditis, myocardial damage, and irritation.
Related Conference of Cardiac manifestations of coronavirus
March 09-10, 2026
21th International Conference on Allergic Diseases and Clinical Immunology
Singapore City, Singapore
April 16-17, 2026
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
London, UK
Cardiac manifestations of coronavirus Conference Speakers
Recommended Sessions
- Cardiac manifestations of coronavirus
- Coronaviruses (COVID-19)
- COVID-19 and Environmental Health
- COVID-19 Clinical Trails
- COVID-19 Drug design and Development
- Epidemiological Characteristics of COVID-19
- Food and Nutrition
- Genomics and transmissibility
- Infectious Diseases Covid-19
- Mental health
- Monoclonal antibody treatments
- Omicron
- SARS-CoV-2 variants
- Severe Acute Respiratory Syndrome Coronavirus 2
- Therapeutics and COVID-19
- Vaccines
- Virology
Related Journals
Are you interested in
- Allergy, Hypersensitivity & Immune Tolerance - Immunology 2026 (France)
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Autoimmune & Inflammatory Disorders - Immunology 2026 (France)
- Cancer Immunology & Tumor Microenvironment - Immunology 2026 (France)
- Cellular Signaling & Cell Fate Determination - Immunology 2026 (France)
- Clinical and Translational Immunology - Immunology 2026 (France)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immunogenetics & Epigenetic Regulation - Immunology 2026 (France)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Immunometabolism - Immunology 2026 (France)
- Immunotherapy & Immune Modulation - Immunology 2026 (France)
- Infectious Diseases - Antibiotics 2026 (UK)
- Infectious Diseases & Host–Pathogen Interactions - Immunology 2026 (France)
- Innate and Adaptive Immune Mechanisms - Immunology 2026 (France)
- Innovations in Cell Biology & Imaging Technologies - Immunology 2026 (France)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Molecular & Cellular Immunology - Immunology 2026 (France)
- Neuroimmunology & Brain–Immune Interactions - Immunology 2026 (France)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- Stem Cells & Regenerative Immunology - Immunology 2026 (France)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
- Vaccines & Vaccine Technology - Immunology 2026 (France)

